literature

HIV mutation literature information.

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.

PMID: 18390885 2008 The Journal of antimicrobial chemotherapy

Abstract: The fosamprenavir/ritonavir score A was introduced in the 2006 ANRS algorithm along with isolated mutations I50V and V32I + I47V.

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

PMID: 18505178 2008 Antiviral therapy

Abstract: We determined the genotypic score I13V+V32I+L33F/I/V+E35D+ M361/L/V+I47V+F53L+I62V.

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

PMID: 18690163 2008 AIDS (London, England)

Abstract: Emergence of DRV-associated-resistance mutations was observed in 72% (18/25) of patients, at codons L89I/M/V (32%), V32I (28%), V11I (20%), I47V/A (20%), I54L/M (20%), L33F/I (16%) and I50V (16%).

Combating HIV resistance - focus on darunavir.

PMID: 19209258 2008 Therapeutics and clinical risk management

Abstract: Darunavir resistance-associated mutations have been defined as V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V.

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.

PMID: 17425479 2007 Expert opinion on pharmacotherapy

Abstract: The TPV mutation score includes L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D and I84V.

HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

PMID: 17500586 2007 PLoS computational biology

Result: Finally, the lower-left part of the figure contains a cluster with seven of the 11 mutations recently reported to be associated with phenotypic and clinical resistance to the newest PI, darunavir (V32I, L33F, I47V, I50V, I54L/M, and L76V).

Result: In contrast, I54L/M were significantly associated only with L33F, M46I, I47V, I84V, and L90M.

Result: The mutations included in this analysis were the 22 positively associated mutations in Table 1 and 13 additional clinically relevant PI-resis

Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.

PMID: 17502734 2007 AIDS (London, England)

Abstract: Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on a darunavir/ritonavir-containing regimen.

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

PMID: 17646201 2007 The Journal of antimicrobial chemotherapy

Abstract: For minor darunavir resistance mutations, the rates were V11I 3.3%, V32I 3.9%, L33F 11%, I47V 2.1%, I54L 2.3%, G73S 12.8% and L89V 2.4%.

[Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].

PMID: 18396668 2007 Zhonghua liu xing bing xue za zhi

Abstract: Some protease (PR) drug-resistant mutations were found in these samples, such as D30N (2.27%), D30G (2.27%), M46I (4.55%), M46N (2.27%), I47V (4.55%), I84V (4.55%), I84L (2.27%), N88S (2.27%) and L90S (2.27%) that all belonged to major drug-resistant but A71T (29.55%) belonged to minor resistance mutations Five treated patients were detected having mutations associated RT drug resistance: M41L (5.26%), A62V (5.26%),D67N (5.26%), protease bearing drug resistant substitutions of V32I, I47V and V82I.

PMID: 16492163 2006 Chemical biology & drug design

Abstract: In this work, the molecular details of the effect of I47V mutation is investigated using molecular dynamics simulation.

Abstract: Noteworthy, it is less susceptible to several common mutations, but it is still susceptible to a few mutations, including I47V which appears to be specific for JE-2147.

Browser Board

Co-occurred Entities

Filtrator